Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations

Journal of the National Cancer Institute

Volumn 91, Issue 24, 1999, Pages 2112-2117

  Robson, Mark ^a   Levin, Deborah ^a   Federici, Mark ^a   Satagopan, Java ^a   Bogolminy, Faina ^a   Heerdt, Alexandra ^a   Borgen, Patrick ^a   McCormick, Beryl ^a   Hudis, Clifford ^a   Norton, Larry ^a   Boyd, Jeff ^a   Offit, Kenneth ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; AUTORADIOGRAPHY; BREAST CANCER; CANCER INVASION; CANCER RISK; CLINICAL ARTICLE; CONSERVATIVE TREATMENT; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SURGICAL APPROACH; TREATMENT PLANNING;

EID: 17144444025     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.24.2112     Document Type: Article

References (52)

1. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer 1996;77: 2318-24.
2. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266: 66-71.
3. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-92.
4. ASHG report. Statement on informed consent for genetic research. The American Society of Human Genetics. Am J Hum Genet 1996;59: 471-4.
5. Strauss WB. Preparation of genomic DNA from mammalian tissue. In: Ausubel FM, Brent R. Kingston RE, editors. Current protocols in molecular biology. Vol 1. New York (NY): John Wiley & Sons; 1998. p. 2.2.1-2.2.3.
6. Oddoux C, Struewing JP, Clayton CM, Neuhausen S, Brody LC, Kaback M, et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 1996;14:188-90.
7. Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996;14:185-7.
8. Struewing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 1995;11:198-200.
9. van der Heijden O, Chiu HC, Park TC, Takahashi H, LiVolsi VA, Risinger JI, et al. Allelotype analysis of uterine leiomyoma: localization of a potential tumor suppressor gene to a 4-cM region of chromosome 7q. Mol Carcinog 1998;23:243-7.
10. Rhei E, Bogomolniy F, Federici MG, Maresco DL, Offit K, Robson ME, et al. Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers. Cancer Res 1998;58:3193-6.
11. Boyd J, Sonoda Y, Federici MG, Bogomolniy F, Rhei E, Maresco DL, et al. Clinical and pathologic features of hereditary ovarian cancers associated with germline mutations in BRCA1 or BRCA2 [abstract]. Gynecol Oncol 1999;72:444.
12. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141-54.
13. th ed. Philadelphia (PA): Lippincott; 1992.
14. Burke W, Daly M, Garber J, Botkin J, Kahn MJ, Lynch P, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 1997;277:997-1003.
15. Eisinger F, Alby N, Bremond A, Dauplat J, Espie M, Janiaud P, et al. Recommendations for medical management of hereditary breast and ovarian cancer: the French National Ad Hoc Committee. Ann Oncol 1998;9:939-50.
16. Fourquet A, Campana F, Zafrani B. Mosseri V, Vielh P, Durand JC, et al. Prognostic factors of breast recurrence in the conservative management of early breast cancer: a 25-year followup. Int J Radiat Oncol Biol Phys 1989;17: 719-25.
17. Fowble BL, Schultz DJ, Overmoyer B, Solin LJ, Fox K, Jardines L, et al. The influence of young age on outcome in early stage breast cancer. Int J Radiat Oncol Biol Phys 1994;30: 23-33.
18. Harrold EV, Turner BC, Matloff ET, Pathare P, Beinfleld M, McKhann C, et al. Local recurrence in the conservatively treated breast cancer patient: a correlation with age and family history. Cancer J Sci Am 1998;4:302-7.
19. Kurtz JM, Spitalier JM, Amalric R, Brandone H, Ayme Y, Bressac C, et al. Mammary recurrences in women younger than forty. Int J Radial Oncol Biol Phys 1988;15:271-6.
20. Kurtz JM, Jacquemier J, Amalric R, Brandone H, Ayme Y, Hans D, et al. Why are local recurrences after breast-conserving therapy more frequent in younger patients? J Clin Oncol 1990;8:591-8.
21. Recht A, Connolly JL, Schnitt SJ, Silver B, Rose MA, Love S, et al. The effect of young age on tumor recurrence in the treated breast after conservative surgery and radiotherapy. Int J Radiat Oncol Biol Phys 1988;14:3-10.
22. Chabner E, Nixon A, Gelman R, Hetelekidis S, Recht A, Bornstein B, et al. Family history and treatment outcome in young women after breasl-conserving surgery and radiation therapy for early-stage breast cancer. J Clin Oncol 1998;16:2045-51.
23. Haas JA, Schultz DJ, Peterson ME, Solin LJ. An analysis of age and family history on outcome after breast-conservation treatment: the University of Pennsylvania experience. Cancer J Sci Am 1998;4:308-15.
24. Turner B, Harrold E, Matloff E, Smith T, Gumbs AA, Beinfield M, et al. BRCA1/ BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations. J Clin Oncol 1999;17:3017-24.
25. Robson M, Levin D, Brown K, Haas B, Hampel H, Schulz C, et al. Results of breast conservation therapy (BCT) for invasive breast cancer in women with BRCA mutations [abstract]. Proc ASCO 1998;17:548a.
26. Verhoog LC, Brekelmans CT, Seynaeve C, van den Bosch LM, Dahmen G, van Geel AN, et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 1998;351:316-21.
27. Pierce L, Strawderman M, Narod S, Olivotto I. Eisen A, Dawson L, et al. No deleterious effects of radiotherapy in women who are heterozygote for a BRCA-1 or BRCA-2 mutation following breast conservation therapy [ab-stract]. Proc ASCO 1999;18:86a.
28. Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P, et al. Hereditary breast cancer: pathohiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 1996;77: 697-709.
29. Porter DE, Dixon M, Smyth E, Steel CM. Breast cancer survival in BRCA1 carriers. Lancet 1991;341:184-5.
30. Porter DE, Cohen BB, Wallace MR, Smyth E, Chetty U, Dixon JM, et al. Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12-21. Br J Surg 1994;81:1512-5.
31. Johannsson OT, Ranstam J, Borg A, Olsson H. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol 1998;16:397-404.
32. Robson M, Gilewski T, Haas B, Levin D, Borgen P, Rajan P, et al. BRCA-associated breast cancer in young women. J Clin Oncol 1998; 16:1642-9.
33. Ansquer Y, Gautier C, Fourquet A, Asselain B. Stoppa-Lyonnet D. Survival in early-onset BRCA1 breast-cancer patients. Institut Curie Breast Cancer Group. Lancet 1998;352:541.
34. Foulkes WD, Wong N, Brunet JS, Begin LR, Zhang JC, Martinez JJ, et al. Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clin Cancer Res 1997;3:2465-9.
35. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 1997; 349:1505-10.
36. Eisinger F, Stoppa-Lyonnet D, Longy M, Kerangueven F, Noguchi T, Bailly C, et al. Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res 1996;56:471-4.
37. Eisinger F, Nogues C, Birnbaum D, Jacquemier J, Sobol H, BRCA1 and medullary breast cancer. JAMA 1998;280:1227-8.
38. Jacquemier J, Eisinger F, Birnbaum D, Sobol H. Histoprognostic grade in BRCA1-associated breast cancer. Lancet 1995;345: 1503.
39. Robson M, Rajan P, Rosen PP, Gilewski T, Hirschaut Y, Pressman P, et al. BRCA-associated breast cancer: absence of a characteristic immunophenotype. Cancer Res 1998; 58:1839-42.
40. Johannsson OT, Idvall I, Anderson C, Borg A, Barkardottir RB, Egilsson V, et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 1997;33: 362-71.
41. Loman N, Johannsson O, Bendahl PO, Borg A, Ferno M, Olsson H. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer 1998;83:310-9.
42. Osin P, Gusterson BA, Philp E, Waller J, Bartek J, Peto J, et al. Predicted anti-oestrogen resistance in BRCA-associaled familial breast cancers. Eur J Cancer 1998;34:1683-6.
43. Crook T, Crossland S, Crompton MR, Osin P, Gusterson BA. p53 mutations in BRCA1-associated familial breast cancer. Lancet 1997; 350:638-9.
44. Crook T, Brooks LA, Crossland S, Osin P, Barker KT, Waller J, et al. p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours. Oncogene 1998;17:1681-9.
45. Phillips KA, Nichol K, Ozcelik H, Knight J, Done SJ. Goodwin PJ, et al. Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations. J Natl Cancer Inst 1999;91:469-73.
46. Frank TS, Manley SA, Olopade OI, Cummings S, Garber JE, Bernhardt B, et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 1998;16:2417-25.
47. Robson ME, Offit K, New BRCA2 mutation in an Ashkenazi Jewish family with breast and ovarian cancer. Lancet 1997;350:117-8.
48. Schubert EL, Lee MK, Mefford HC, Argonza RH, Morrow JE, Hull J, et al. BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2. Am J Hum Genet 1997;60:1031-40.
49. Newman B, Mu H, Butler LM, Millikan RC, Moorman PG, King MC. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 1998; 279:915-21.
50. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998;62:676-89.
51. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8.
52. Chen J, Silver DP, Walpita D, Cantor SB, Gazdar AF, Tomlinson G, et al. Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol Cell 1998;2:317-28.